Iron Chelation as Therapy for HIV and Mycobacterium tuberculosis Co-Infection Under Conditions of Iron Overload
The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
Iron chelators, as treatment for conditions of iron overload, have implications for AIDS and tuberculosis (TB) since excess iron in the system assists HIV and Mycobacterium tuberculosis (M.tb) multiplication. Excess iron, especially due to dietary habits, is almost as common in sub-Saharan Africa as infections by the two organisms. That HIV and M.tb influence each other's replication during co-infection is well established, but in vitro evaluations of concurrent infection of the two under conditions of iron overload and determining whether chelators reverse the effect, are limited. This review provides brief commentary on the possibility of iron chelators presently in clinical use influencing simultaneous HIV-M.tb infections during iron loading and the feasibility of evaluating this in vitro.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These chelators can alter the development of inflammatory diseases, have antiviral properties and can also be used in the treatment of malignancies (Meyer, 2006; Lehmann et al., 2015).”
From Iron at the Centre of Candida albicans Interactions (2018) · cites this paper as Meyer, 2006
In the citing paper
“Iron overload in the host can be due to hereditary or dietary factors and the main therapy for this is through the administration of small molecule chelators (Meyer, 2006).”
From Iron at the Centre of Candida albicans Interactions (2018) · cites this paper as Meyer, 2006
Citations
Cites
Collins, L., & Franzblau, S. G. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.5.1004 · Cited by 1,599
Progress in understanding the pathogenesis of the anemia of chronic disease [see comments]
Means, R. J., & Krantz, S. (1992) · Blood · doi:10.1182/blood.v80.7.1639.1639 · Cited by 681 · cited 1×
“Iron plays a role in the outcome of many infections and overload of the metal can promote the frequency and severity of microorganism infections [12] in addition to altering immune- and other host cell defense responses [13-14].”
BackgroundEffect of Mycobacterium tuberculosis on HIV replication. Role of immune activation
Goletti, D., Weissman, D., Jackson, R. W., Graham, N. M., Vlahov, D., Klein, R. S., Munsiff, S. S., Ortona, L., Cauda, R., & Fauci, A. S. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.157.3.1271 · Cited by 495 · cited 2×
“Conversely, TB is accelerated by co-infection with HIV [1-5] and replication of both of these microorganisms is augmented by iron loading [6-9].”
BackgroundIron, mycobacteria and tuberculosis
Ratledge, C. (2004) · Tuberculosis · doi:10.1016/j.tube.2003.08.012 · Cited by 344
Gobin, J., & Horwitz, M. A. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.4.1527 · Cited by 208
Gobin, J., Moore, C. H., Reeve, J. R., Wong, D. K., Gibson, B. W., & Horwitz, M. A. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.11.5189 · Cited by 180
Impact of tuberculosis (TB) on HIV-1 activity in dually infected patients
Toossi, Z., Mayanja-Kizza, H., Hirsch, C. S., Edmonds, K. L., Spahlinger, T., Hom, D. L., Aung, H., Mugyenyi, P., Ellner, J. J., & Whalen, C. W. (2001) · Clinical and Experimental Immunology · doi:10.1046/j.1365-2249.2001.01401.x · Cited by 167 · cited 2×
“tb infection have been reported in sub-Saharan Africa [4] and 11% of all AIDSrelated deaths are due to tuberculosis [11].”
BackgroundMycobacterial disease, immunosuppression, and acquired immunodeficiency syndrome
Collins, F. M. (1989) · Clinical Microbiology Reviews · doi:10.1128/cmr.2.4.360 · Cited by 157 · cited 1×
“Conversely, TB is accelerated by co-infection with HIV [1-5] and replication of both of these microorganisms is augmented by iron loading [6-9].”
BackgroundIron and Mycobacterium tuberculosis infection
Lounis, N., Truffot-Pernot, C., Grosset, J., Gordeuk, V. R., & Boelaert, J. R. (2001) · Journal of Clinical Virology · doi:10.1016/s1386-6532(00)00136-0 · Cited by 142 · cited 2×
“Excess iron enhances viral replication [7] and mycobacterial multiplication [6] and it does not seem to matter whether patients contract HIV or M.”
BackgroundIron and infection: competition between host and microbes for a precious element
MARX, J. (2002) · Best Practice & Research Clinical Haematology · doi:10.1053/beha.2002.0001 · Cited by 129 · cited 1×
“Iron plays a role in the outcome of many infections and overload of the metal can promote the frequency and severity of microorganism infections [12] in addition to altering immune- and other host cell defense responses [13-14].”
Background
Cited by
Kell, D. B. (2009) · BMC Medical Genomics · doi:10.1186/1755-8794-2-2 · Cited by 554
“[136; 149; 1335; 1352-1371]), and its chelation in a form not available to bacteria offers a route to at least a bacteriostatic kind of antibiotic or to novel therapies based on the lowering of iron available to microbes by using hepcidin [1372].”
BackgroundA major role for ferroptosis in Mycobacterium tuberculosis –induced cell death and tissue necrosis
Amaral, E. P., Costa, D. L., Namasivayam, S., Riteau, N., Kamenyeva, O., Mittereder, L., Mayer-Barber, K. D., Andrade, B. B., & Sher, A. (2019) · Journal of Experimental Medicine · doi:10.1084/jem.20181776 · Cited by 464
“In contrast, iron chelation and mutations in host or bacterial genes affecting iron availability typically restrict pathogen growth (Schaible et al., 2002; Meyer, 2006; Owens et al., 2013; Boradia et al., 2014; Dragset et al., 2015).”
BackgroundKell, D. B. (2010) · Archives of Toxicology · doi:10.1007/s00204-010-0577-x · Cited by 361
“…of superoxide, peroxide and the hydroxyl radical involving poorly liganded iron can exert a positive feedback leading to the death of cells 2009; Meyer 2006; Northrop-Clewes 2008; Rawat et al. 2008; Savarino et al. 1999; Schreck et al. 1992; Szajerka and Jablecki 2007; Traoré and Meyer 2004,…”
BackgroundIron at the Centre of Candida albicans Interactions
Fourie, R., Kuloyo, O. O., Mochochoko, B. M., Albertyn, J., & Pohl, C. H. (2018) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2018.00185 · Cited by 118
“These chelators can alter the development of inflammatory diseases, have antiviral properties and can also be used in the treatment of malignancies (Meyer, 2006; Lehmann et al., 2015).”
BackgroundBasaraba, R. J. (2008) · Tuberculosis · doi:10.1016/s1472-9792(08)70035-0 · Cited by 136
“Iron chelation therapy has been suggested as an alternative therapy in tuberculosis patients as well as those co-infected with HIV.(128,134,135) Therefore, the targeting of lesion-associated iron with iron chelator represents an alternative strategy to treat tuberculosis either alone or in combination with conventiona…”
Background
Metadata
- Authors
- Meyer, D.
- Affiliations
- University of Johannesburg (ZA)
- Corresponding author
- Meyer, Debra
- ORCID
- Meyer, Debra
- Venue
- Current Pharmaceutical Design
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2006-06-01
- Volume
- 12
- Issue
- 16
- Pages
- 1943-1947
- ISSN
- 1381-6128 (ISSN-L)
- OpenAlex
- W2044191483
- Cited by
- 34
- References
- 37
- Citations by year
- 2025: 1 · 2024: 2 · 2022: 1 · 2021: 1 · 2020: 4 · 2019: 2 · 2018: 5 · 2017: 1 · 2015: 1 · 2014: 2 · 2013: 2 · 2012: 1
- FWCI
- 1.83
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Pharmaceutical Design (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
- Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Health Sciences › Medicine › Infectious Diseases › Infectious Diseases and Tuberculosis
- Keywords
- iron chelation, iron overload, HIV, Mycobacterium tuberculosis, tuberculosis-HIV coinfection, iron chelators, sub-Saharan Africa, dietary iron
- MeSH terms
- HIV, Humans, Iron, Iron Chelating Agents, Macrophages, Mycobacterium tuberculosis, Tuberculosis, HIV Infections, Iron Overload
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Iron Chelation as Therapy for HIV and Mycobacterium tuberculosis Co-Infection Under Conditions of Iron Overload. https://app.cochat.ai/papers/10.2174/138161206777442164
- The paper
- Meyer, D. (2006). Iron Chelation as Therapy for HIV and Mycobacterium tuberculosis Co-Infection Under Conditions of Iron Overload. Current Pharmaceutical Design. https://doi.org/10.2174/138161206777442164
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.